Art. 14 Regulation (EU) 2017/745

General obligations of distributors

In forcesince 5 Apr 2017cited 9×
1.

When making a device available on the market, distributors shall, in the context of their activities, act with due care in relation to the requirements applicable.

2.

Before making a device available on the market, distributors shall verify that all of the following requirements are met:

(a)

the device has been CE marked and that the EU declaration of conformity of the device has been drawn up;

(b)

the device is accompanied by the information to be supplied by the manufacturer in accordance with Article 10(11);

(c)

for imported devices, the importer has complied with the requirements set out in Article 13(3);

(d)

that, where applicable, a UDI has been assigned by the manufacturer.

In order to meet the requirements referred to in points (a), (b) and (d) of the first subparagraph the distributor may apply a sampling method that is representative of the devices supplied by that distributor.

Where a distributor considers or has reason to believe that a device is not in conformity with the requirements of this Regulation, it shall not make the device available on the market until it has been brought into conformity, and shall inform the manufacturer and, where applicable, the manufacturer's authorised representative, and the importer. Where the distributor considers or has reason to believe that the device presents a serious risk or is a falsified device, it shall also inform the competent authority of the Member State in which it is established.

3.

Distributors shall ensure that, while the device is under their responsibility, storage or transport conditions comply with the conditions set by the manufacturer.

4.

Distributors that consider or have reason to believe that a device which they have made available on the market is not in conformity with this Regulation shall immediately inform the manufacturer and, where applicable, the manufacturer's authorised representative and the importer. Distributors shall co-operate with the manufacturer and, where applicable, the manufacturer's authorised representative, and the importer, and with competent authorities to ensure that the necessary corrective action to bring that device into conformity, to withdraw or to recall it, as appropriate, is taken. Where the distributor considers or has reason to believe that the device presents a serious risk, it shall also immediately inform the competent authorities of the Member States in which it made the device available, giving details, in particular, of the non-compliance and of any corrective action taken.

5.

Distributors that have received complaints or reports from healthcare professionals, patients or users about suspected incidents related to a device they have made available, shall immediately forward this information to the manufacturer and, where applicable, the manufacturer's authorised representative, and the importer. They shall keep a register of complaints, of non-conforming devices and of recalls and withdrawals, and keep the manufacturer and, where available, the authorised representative and the importer informed of such monitoring and provide them with any information upon their request.

6.

Distributors shall, upon request by a competent authority, provide it with all the information and documentation that is at their disposal and is necessary to demonstrate the conformity of a device.

Distributors shall be considered to have fulfilled the obligation referred to in the first subparagraph when the manufacturer or, where applicable, the authorised representative for the device in question provides the required information. Distributors shall cooperate with competent authorities, at their request, on any action taken to eliminate the risks posed by devices which they have made available on the market. Distributors, upon request by a competent authority, shall provide free samples of the device or, where that is impracticable, grant access to the device.

  • BGH, EuGH-Vorlage vom 21. Dezember 2023 - I ZR 17/23Decision

    … L 117 vom 5. April 2017) folgende Fragen zur Vorabentscheidung vorgelegt: 1. Ist ein Händler gemäß Art. 14 Abs. 1 und 2 Unterabs. 1 Buchst. a der Verordnung (EU) 2017/745 verpflichtet zu prüfen, ob das von ihm auf dem Markt …

    21 Dec 2023 · KORE305492023

  • Judgment of the Court (First Chamber) of 4 June 2026. Dürr Dental SE v Cattani Deutschland Helmes GmbH & Co. KG.Decisioninterprets

    On those grounds, the Court (First Chamber) hereby rules: (1) Article 14(1) and point (a) of the first subparagraph of Article 14(2) of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical …

    4 Jun 2026 · 62024CJ0010

  • Opinion of Advocate General Spielmann delivered on 11 September 2025. Dürr Dental SE v Cattani Deutschland Helmes GmbH & Co. KG.Decision

    What is the scope of the respective obligations of the distributors and the manufacturers of medical devices and, more specifically, what is the scope of the checks to be carried out by the distributors before making a medical device …

    11 Sep 2025 · 62024CC0010

  • Code de la santé publiquer5211-4r5212-8Law

    … 5211-1 leur transmet les informations, documents ou échantillons du dispositif mentionnés aux articles 10, 11, 13 et 14 du règlement (UE) 2017/745 du 5 avril 2017.

  • Opinion of Advocate General Norkus delivered on 9 July 2026. Verband Sozialer Wettbewerb eV v GUT GEKAUFT Reformhäuser GmbH.Decision

    … EU:C:2025:697. 8 In that case, the Court was required to determine the scope of the distributor’s obligations under Article 14(2) of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical …

    9 Jul 2026 · 62025CC0435

  • Judgment of the Court (Sixth Chamber) of 2 July 2026. Zentrale zur Bekämpfung unlauteren Wettbewerbs Frankfurt am Main eV v Diagramm HalbachDecision

    … på listen i UWG’s § 8b, er derfor af den opfattelse, at Diagramm har tilsidesat sine forpligtelser i henhold til artikel 14, stk. 1, og artikel 14, stk. 2, litra a), i forordning 2017/745. Zentrale fremsendte således en advarsel til …

    2 Jul 2026 · 62024CJ0427

  • BGH, Beschluss vom 18. Juni 2025 - I ZR 78/24Decision

    18 Jun 2025 · I_ZR__78-24

  • BGH, EuGH-Vorlage vom 18. Juni 2025 - I ZR 78/24Decision

    … es nicht weiter auf dem Markt bereitstellen, selbst wenn der Hersteller die Beanstandungen für unbegründet hält (zu Art. 14 Abs. 1 und 2 Unterabs. 3 der Verordnung [EU] 2017/745 über Medizinprodukte vgl. BGH, Beschluss vom 21. Dezember …

    18 Jun 2025 · KORE715352025

  • BGH, Beschluss vom 21. Dezember 2023 - I ZR 17/23Decision

    21 Dec 2023 · I_ZR__17-23